DK0480659T3 - Anvendelse af angiotensin-II-antagonister i behandlingen af hyperurikæmi - Google Patents

Anvendelse af angiotensin-II-antagonister i behandlingen af hyperurikæmi

Info

Publication number
DK0480659T3
DK0480659T3 DK91309176.5T DK91309176T DK0480659T3 DK 0480659 T3 DK0480659 T3 DK 0480659T3 DK 91309176 T DK91309176 T DK 91309176T DK 0480659 T3 DK0480659 T3 DK 0480659T3
Authority
DK
Denmark
Prior art keywords
treatment
hyperuricaemia
angiotensin
antagonists
angiotension
Prior art date
Application number
DK91309176.5T
Other languages
English (en)
Inventor
Mitsuyosi Nakasima
Kazuo Kamei
Mitsutaka Kanamaru
Ikuo Ohta
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK0480659T3 publication Critical patent/DK0480659T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
DK91309176.5T 1990-10-08 1991-10-07 Anvendelse af angiotensin-II-antagonister i behandlingen af hyperurikæmi DK0480659T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27021490 1990-10-08

Publications (1)

Publication Number Publication Date
DK0480659T3 true DK0480659T3 (da) 1996-09-23

Family

ID=17483133

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91309176.5T DK0480659T3 (da) 1990-10-08 1991-10-07 Anvendelse af angiotensin-II-antagonister i behandlingen af hyperurikæmi

Country Status (8)

Country Link
US (1) US5260322A (da)
EP (1) EP0480659B1 (da)
JP (1) JPH0662410B2 (da)
AT (1) ATE142107T1 (da)
CA (1) CA2052884C (da)
DE (1) DE69121827T2 (da)
DK (1) DK0480659T3 (da)
ES (1) ES2091877T3 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
NO304429B1 (no) * 1992-12-17 1998-12-14 Sankyo Co Bifenylderivater, farmas°ytisk preparat og deres anvendelse for fremstilling av et medikament for behandling av hypertensjon og hjertesykdom
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
DE60105020T2 (de) 2000-06-07 2005-08-18 Almirall-Prodesfarma S.A. 6-phenylpyrrolopyrimidindion derivate
US7799794B2 (en) 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
PT1471054E (pt) 2002-01-11 2009-09-23 Daiichi Sankyo Co Ltd Derivado de aminoálcool ou derivado de ácido fosfónico e composição medicinal que os contém
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
WO2004092346A2 (en) * 2003-04-15 2004-10-28 The Regents Of The University Of California Small molecule inhibition of a pdz-domain interaction
RU2332212C2 (ru) 2004-02-24 2008-08-27 Санкио Компани, Лимитед Аминоспирт
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
RU2007103834A (ru) * 2004-07-01 2008-08-10 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) Ингибирование взаимодействия pdz-доменов малыми молекулами
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
KR100953878B1 (ko) * 2004-09-02 2010-04-22 테바 파마슈티컬 인더스트리즈 리미티드 올메살탄 메독소밀의 정제
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
SG183721A1 (en) 2007-11-27 2012-09-27 Ardea Biosciences Inc Novel compounds and compositions and methods of use
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
CA2722624C (en) 2008-04-30 2017-03-21 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
BR112012018695A2 (pt) 2010-01-27 2016-04-12 Boehringer Ingelheim Int compostos pirazol como antagonistas crth2
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
US9206164B2 (en) 2011-03-25 2015-12-08 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Also Published As

Publication number Publication date
JPH0662410B2 (ja) 1994-08-17
EP0480659B1 (en) 1996-09-04
EP0480659A3 (en) 1992-06-17
DE69121827D1 (de) 1996-10-10
JPH0525043A (ja) 1993-02-02
CA2052884C (en) 2003-12-30
ES2091877T3 (es) 1996-11-16
US5260322A (en) 1993-11-09
EP0480659A2 (en) 1992-04-15
CA2052884A1 (en) 1992-04-09
DE69121827T2 (de) 1997-02-27
ATE142107T1 (de) 1996-09-15

Similar Documents

Publication Publication Date Title
DK0480659T3 (da) Anvendelse af angiotensin-II-antagonister i behandlingen af hyperurikæmi
DK0714392T3 (da) Heterocykliske neurokinin-antagonister
SE8802570D0 (sv) New use of 5ht-3 antagonists
NO930817D0 (no) Imidazolderivater med bifenylsulfonylurea- eller bifenylsulfonyluretan-sidekjeder, fremgangsmaate for deres fremstilling og deres anvendelse
FI914533A7 (fi) Fibrinogeenireseptoriantagonisteja
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
FI934894A7 (fi) Fibrinogeenireseptorin antagonisteja
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
FI903331A7 (fi) Angiotensiini-II-antagonisteina käyttökelpoisia substituoituja kinatsolinoneja
FI905022A7 (fi) Fibrinogeenin reseptorin antagonisteja
DE69232323D1 (de) Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
FI905023A7 (fi) Fibrinogeenin reseptorin antagonisteja
ATE219077T1 (de) Endothelin antagoniste
FI913048A7 (fi) Bisykliset heterosykliset yhdisteet
ES2167457T3 (es) Nuevo uso medicinal de un antagonista de 5ht3.
FI894007L (fi) Neuropeptid y-antagonister.
FI953916L (fi) Fibrinogeenireseptoriantagonisteja
DE69426452D1 (de) Fibrinogen receptor antagonisten
DE69133390D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung von hämorragischem schlaganfall
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
IS4597A (is) Ný lyfjafræðileg notkun AII-viðtaka mótlyfja
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
FI943359L (fi) Atsasykliset-heterosykliset yhdisteet angiotensiini II reseptoriantagonisteina
DK266289D0 (da) Alfa-adrenerge receptorantagonister, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse antagonister
DK0661058T3 (da) Anvendelse af bradykininantagonister til behandling af virussygdomme